Low-dose prednisone added to standard therapy for heart involvement in Fabry disease
Tests prednisone added to standard treatment in adults with Fabry disease affecting the heart.
Key facts
- Who runs it
- Medical University Of Lodz
- Where
- Katowice and Lodz, PolandSee the 2 sites
- Trial code
- Registry title
- Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 40 people, planned
- Started
- 5 Mar 2026
- Expected to end
- 31 Aug 2030
- Type of study
- Interventional
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Fabry disease who already get enzyme replacement therapy or migalastat and who have signs of heart involvement. It tests low dose prednisone added to that treatment.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Fabry disease with heart involvement: at least one abnormal finding on ECG, heart ultrasound or heart MRI, and troponin T above 14 ng/l
- Earlier treatment
- Must be on enzyme replacement therapy (agalsidase alfa or agalsidase beta) or chaperone therapy with migalastat. Must not have taken variable-dose corticosteroids for other reasons less than 3 months before joining.
- Biomarker or test result
- High-sensitivity troponin T level above 14 ng/l
Main reasons for not taking part
- Pregnancy or breastfeeding
- eGFR below 30 ml/m2/min
- Diabetes
- Cataracts
- Stomach or duodenal ulcer, or gastrointestinal bleeding in the past 12 months
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Giving informed consent
- Age at least 18 years on the day of the screening visit
- Ongoing treatment for Fabry disease: Enzyme replacement therapy with agalsidase alfa or agalsidase beta, or Chaperone therapy with migalastat
- Cardiac involvement in Fabry disease (meeting at least one of the following criteria a-c): a. electrocardiographic abnormalities defined as: - short PR (less than 120 ms) or - long PR (200 ms or more) or - bradycardia (heart rate less than <60 beats per minute) or - chronotropic failure or - repolarization abnormalities. b. echocardiographic abnormalities defined as: - left ventricular hypertrophy (wall thickness of 12 mm or more), or - reduced global longitudinal strain (GLS<-16%), or - dilatation of the aortic annulus >22 mm/m2, or - thickening of the mitral and aortic valve leaflets (>5 mm and 2 mm, respectively) with at least mild valvular regurgitation. c. cardiac MRI abnormalities defined as: - left ventricular hypertrophy defined as LVMI>2SD above the mean based on age- and gender-specific reference ranges, or - papillary muscle hypertrophy, or - the presence of late gadolinium enhancement (LGE)
- High-sensitivity troponin T level above >14 ng/l
- Contraceptive readiness (for women)
Who cannot take part
- Concomitant treatment with variable-dose corticosteroids for other indications less than 3 months prior to study inclusion
- Planned attenuated vaccine
- Episode of gastrointestinal bleeding within 12 months prior to starting treatment
- Patient not treated with enzyme replacement therapy or chaperone therapy
- Hypersensitivity to any component of the test drug compound
- Diagnosis of mental illness
- Diabetes
- Peptic ulcer disease of the stomach and/or duodenum
- Chronic and/or systemic fungal infection
- Coexistence with autoimmune disease
- eGFR<30ml/m2/min
- Age < 18 years at the time of screening
- Reluctance to adhere to a scheduled schedule of visits
- Pregnancy (for women)
- Lactation (for women)
- Cataracts
- Inability to give informed consent to participate in the study
Where in Poland
- Gornoslaskie Centrum Medyczne Im Prof. Leszka Gieca Sląskiego Uniwersytetu Medycznego W KatowicachKatowice, PolandTaking people
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W LodziLodz, PolandTaking people
About the trial
What the trial wants to find out
The main objective of the study is to evaluate whether the use of prednisone - as an adjunctive treatment to standard therapy (ERT or CHT) - can effectively improve cardiac function by reducing myocardial inflammation, considered one of the key pathological mechanisms in Fabry cardiomyopathy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial
- Plain-language title
- Low-dose prednisone added to standard therapy for heart involvement in Fabry diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 4 November 2026